טוען...
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
PURPOSE: To determine the maximum tolerated dose (MTD) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors. METHODS: Patients with ECOG performance status 0–1 and adequate organ function were enrolled. On days 1, 8, and 15 of a 28-day cycle, patie...
שמור ב:
| Main Authors: | , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3556988/ https://ncbi.nlm.nih.gov/pubmed/18379785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0733-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|